Hepatorenal syndrome: A severe, but treatable, cause of kidney failure in cirrhosis

American Journal of Kidney Diseases

Volumn 59, Issue 6, 2012, Pages 874-885

  Fagundes, Cláudia ^a   Ginès, Pere ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

ascites; chronic liver diseases; Cirrhosis

Indexed keywords

ALBUMIN; CEFTRIAXONE; CREATININE; TERLIPRESSIN;

ADULT; ARTERIAL CIRCULATION; ARTERIAL PRESSURE; ARTICLE; ASCITES; BACTERIAL PERITONITIS; BILIRUBIN BLOOD LEVEL; BLOOD VOLUME; CASE REPORT; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DISEASE SEVERITY; GLOMERULUS FILTRATION RATE; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; KIDNEY ARTERY; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; PORTAL HYPERTENSION; SPLANCHNIC BLOOD FLOW; SURVIVAL; SURVIVAL TIME; VASOCONSTRICTION; VASODILATATION;

ALBUMINS; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; HEPATORENAL SYNDROME; HUMANS; KIDNEY FUNCTION TESTS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; LYPRESSIN; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84861362293     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2011.12.032     Document Type: Article

References (107)

1. R. Hecker, S. Sherlock Electrolyte and circulatory changes in terminal liver failure Lancet 271 6953 1956 1121 1125
2. E.T. Schroeder, L. Shear, S.M. Sancetta, G.J. Gabuza Renal failure in patients with cirrhosis of the liver Evaluation of intrarenal blood flow by para-aminohippurate extraction and response to angiotensin Am J Med 43 6 1967 887 896
3. M. Epstein, D.P. Berck, N.K. Hollemberg Renal failure in the patient with cirrhosis The role of active vasoconstriction Am J Med 49 2 1970 175 185
4. V. Arroyo, P. Ginès, A. Gerbes Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis Hepatology 23 1 1996 164 176
5. F. Salerno, A. Gerbes, P. Ginès, F. Wong, V. Arroyo Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis Gut 56 9 2007 1310 1318
6. R.L. Mehta, J.A. Kellum, S.V. ηαη Acute Kidney Injury Network Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury Crit Care 11 2 2007 R31
7. F. Wong, M.K. Nadim, J.A. Kellum Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis Gut 60 5 2011 702 709
8. E. Verna, E. Farrand, E. Pichardo Urinary neutrophil gelatinase associated lipocalin (UNGAL) distinguishes type of kidney failure and predicts mortality in patients with cirrhosis [abstract] Hepatology 50 suppl 4 2009 311A
9. C. Fagundes, M.N. Pepin, M. Guevara Evaluation of four different urinary biomarkers in the assessment of renal failure in cirrhosis Role for urinary neutrophil gelatinase associated lipocalin [abstract] Hepatology 54 4 2011 1234A
10. A. Ginès, A. Escorsell, P. Ginès Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites Gastroenterology 105 1 1993 229 236
11. R. Planas, S. Montoliu, B. Ballesté Natural history of patients hospitalized for management of cirrhotic ascites Clin Gastroenterol Hepatol 4 11 2006 1385 1394
12. F.L. Lieberman Functional renal failure in cirrhosis Gastroenterology 58 1 1970 108 110
13. S. Iwatsuki, M.M. Popovtzer, J.L. Corman Recovery from "hepatorenal syndrome" after orthotopic liver transplantation N Engl J Med 289 22 1973 1155 1159
14. A. Rimola, J. Gavaler, R.R. Schade, S. el-Lankany, T.E. Starzl, D.H. Van Thiel Effects of renal impairment on liver transplantation Gastroenterology 93 1 1987 148 156
15. P. Ginès, R.W. Schrier Renal failure in cirrhosis N Engl J Med 361 13 2009 1279 1290
16. P. Ginès, A. Cárdenas, R.W. Schrier Liver disease and the kidney R.W. Schrier, Diseases of the Kidney and Urinary Tract 8th ed. 2007 Lippincott Williams & Wilkins Philadelphia, PA 2179 2205
17. R.W. Schrier, V. Arroyo, M. Bernardi, M. Epstein, J.H. Henriksen, J. Rodés Peripheral arterial vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis Hepatology 8 5 1988 1151 1157
18. L. Ruiz-del-Arbol, A. Monescillo, C. Arocena Circulatory function and hepatorenal syndrome in cirrhosis Hepatology 42 2 2005 439 447
19. A. Krag, F. Bendtsen, J.H. Henriksen, S. Moller Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites Gut 59 1 2010 105 110
20. L. Ruíz-del-Arbol, J. Urman, J. Fernández Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis Hepatology 38 5 2003 1210 1218
21. K. Brinch, S. Moller, F. Bendsten Plasma volume expansion by albumin in cirrhosis Relation to blood volume distribution, arterial compliance and severity of disease J Hepatol 39 1 2003 24 31
22. V. Arroyo, P. Ginès, A. Rimola Renal function abnormalities, prostaglandins, and effects of non steroidal anti-inflammatory drugs in cirrhosis with ascites An overview with an emphasis on pathogenesis Am J Med 25 1986 104 122 81 (2B)
23. P.Y. Martin, P. Ginès, R.W. Schrier Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis N Engl J Med 339 8 1998 533 541
24. Y. Iwakiri, R.J. Groszmann The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule Hepatology 43 2 suppl 1 2006 S121 S131
25. J. Ros, J. Clària, J. To-Figueras Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat Gastroenterology 122 1 2002 85 93
26. R. Wiest, S. Das, G. Cadelina, G. Garcia-Tsao, S. Milstien, R.J. Groszmann Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility J Clin Invest 104 9 1999 1223 1233
27. R. Wiest, G. Garcia-Tsao Bacterial translocation (BT) in cirrhosis Hepatology 41 3 2005 422 433
28. A. Albillos, A. de la Hera, M. González Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement Hepatology 37 1 2003 208 217
29. R. Francés, P. Zapater, J.M. González-Navajas Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis Hepatology 47 3 2008 978 985
30. J.P. Chin-Dusting, B. Rasaratnam, G.L. Jennings, F.J. Dudley Effect of fluoroquinolone on the enhanced nitric oxide-induced peripheral vasodilation seen in cirrhosis Ann Intern Med 127 11 1997 985 988
31. B. Rasaratnam, D. Kaye, G. Jennings, F. Dudley, J. Chin-Dusting The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis: a randomized trial Ann Intern Med 139 3 2003 186 193
32. J. Fernández, M. Navasa, R. Planas Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis Gastroenterology 133 3 2007 818 824
33. Y. Iwakiri Endothelial dysfuncytion in the regulation of cirrhosis and portal hypertension [published online ahead of print] Liver Int 32 2 2012 199 213
34. M. Morales-Ruiz, S. Tugues, W. Jiménez Angiogenesis and vascular growth in liver diseases P. Ginès, P.S. Kamath, V. Arroyo, Chronic Liver Failure 2011 Springer New York, NY 343-260
35. J.H. Henriksen, F. Bendsten, T.I. Sorensen Reduced central blood volume in cirrhosis Gastroenterology 97 1989 1506 1513
36. M. Kiska-Kanowitz, J.H. Henriksen, M. Soren Blood volume distribution in patients with cirrhosis: aspects of the dual head gamma-camera technique J Hepatol 35 5 2001 605 612
37. S.A. Alqahtani, T.R. Fouad, S.S. Lee Cirrhotic cardiomyopathy Semin Liver Dis 28 1 2008 59 69
38. S. Moller, J.H. Henriksen Cirrhotic cardiomyopathy J Hepatol 53 1 2010 179 190
39. J. Acevedo, J. Fernández, M. Castro, D. Roca, P. Ginès, V. Arroyo Impact of relative adrenal insufficiency on circulatory function and mortality in advanced cirrhosis [abstract] J Hepatol 54 suppl 2011 S61
40. F. Wong, K. Moore, J. Dingemanse, R. Jalan Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome Hepatology 47 1 2008 160 168
41. A. Maroto, P. Ginès, V. Arroyo Brachial and femoral artery blood flow in cirrhosis: relationship to kidney dysfunction Hepatology 17 5 1993 788 793
42. M. Guevara, C. Bru, P. Ginès Increased cerebral vascular resistance in cirrhotic patients with ascites Hepatology 28 1 1998 39 44
43. J. Fernández, M. Navasa, J.C. Garcia-Pagan Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis J Hepatol 41 2004 384 390
44. M. Guevara, P. Ginès, G. Fernández-Esparrach Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion Hepatology 27 1 1998 35 41
45. J.H. Henriksen Regulation of the extracellular fluid volume and renal function Liver failure P. Ginès, P.S. Kamath, V. Arroyo, Chronic Liver Failure 2011 Springer New York, NY 239 268
46. C. Alessandria, O. Ozdogan, M. Guevara MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation Hepatology 41 6 2005 1282 1289
47. M. Martín-Llahí, M. Guevara, A. Torre Prognostic importance of the cause of renal failure in patients with cirrhosis Gastroenterology 140 2 2011 488 496
48. C. Alessandria, A. Ottobrelli, W. Debernardi-Venon Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded pilot study J Hepatol 47 4 2007 499 505
49. R. Jalan Acute-on-chronic liver failure: from concept to a new syndrome Curr Opin Crit Care 17 2 2011 152
50. G.H. Pereira, M. Guevara, M. Pavesi MELD - sodium predicts survival and development of type 1 hepatorenal syndrome in patients with type 2 hepatorenal syndrome [abstract] J Hepatol 54 suppl 1 2011 S381
51. V. Arroyo, C. Terra, P. Ginès Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome J Hepatol 46 5 2007 935 946
52. A. Follo, J.M. Llovet, M. Navasa Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis Hepatology 20 6 1994 1495 1501
53. M. Navasa, A. Follo, X. Filella Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality Hepatology 27 5 1998 1227 1232
54. R. Terg, A. Gadano, M. Cartier Serum creatinine and bilirubin predict renal failure and mortality in patients with spontaneous bacterial peritonitis: a retrospective study Liver Int 29 3 2009 415 419
55. P. Sort, M. Navasa, V. Arroyo Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis N Engl J Med 341 6 1999 403 409
56. C. Terra, M. Guevara, A. Torre Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score Gastroenterology 129 6 2005 1944 1953
57. D. Thabut, J. Massard, A. Gangloff Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure Hepatology 46 6 2007 1872 1882
58. C. Fagundes, M. Guevara, M. Martín-Llahí Hepatorenal syndrome associated with bacterial infections in cirrhosis Prognostic relevance and importance of circulatory dysfunction [abstract] J Hepatol 54 suppl 1 2011 S380
59. F. Salerno, M. Cazzaniga, M. Merli Diagnosis, treatment and survival of patients with hepatorenal syndrome A survey on daily medical practice J Hepatol 55 6 2011 1241 1248
60. S. Fasolato, P. Angeli, L. Dallagnese Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features Hepatology 45 1 2007 223 229
61. A. Cárdenas, P. Ginès, J. Uriz Renal failure after gastrointestinal bleeding in cirrhosis: incidence, characteristics, predictive factors and prognosis Hepatology 34 4, pt 1 2001 671 676
62. P. Ginès, Ll Titó, V. Arroyo Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis Gastroenterology 94 6 1988 1493 1502
63. P. Ginès, P. Angeli, K. Lenz European Association for the Study of the Liver EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis J Hepatol 53 3 2010 397 417
64. M. Cazzaniga, F. Salerno, G. Pagnozzi Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt Gut 56 6 2007 869 875
65. R. Bataller, P. Ginès, M. Guevara, V. Arroyo Hepatorenal syndrome Semin Liver Dis 17 3 1997 233 247
66. P. Ginès, M. Guevara, V. Arroyo, J. Rodés Hepatorenal syndrome Lancet 362 9398 2003 1819 1827
67. F. Salerno, S. Badalamenti Drug-induced renal failure in cirrhosis P. Ginès, V. Arroyo, J. Rodés, R.W. Schrier, Ascites and Renal Dysfunction in Liver Disease 2005 Blackwell Publishing Oxford, UK 372 382
68. M. Schepke, B. Appenrodt, J. Heller, J. Zielinski, T. Sauerbruch Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: results of a prospective study Liver Int 26 7 2006 834 839
69. F. Fabrizi, F.F. Poordad, P. Martin Hepatitis C infection and the patient with end-stage renal disease Hepatology 36 2 2002 3 10
70. C. Francoz, D. Glotz, R. Moreau, F. Durand The evaluation of renal function and disease in patients with cirrhosis J Hepatol 52 4 2010 605 613
71. G. Targher, L. Bertolini, S. Rodella, G. Lippi, G. Zoppini, M. Chonchol Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis Clin J Am Soc Nephrol 5 12 2010 2166 2171
72. J.M. Trawalé, V. Paradis, P.E. Rautou The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study Liver Int 30 5 2010 725 732
73. A. Umgelter, W. Reindl, K.S. Wagner Effects of plasma expansion with albumin and pracentesis on hemodynamics and kidney function in critically ill cirrhotic patients with tense ascites and hepatorenal syndrome: a prospective uncontrolled trial Crit Care 12 1 2008 R4
74. F. Salerno, M. Guevara, M. Bernardi Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis Liver Int 30 2010 937 947
75. J. Uriz, P. Ginès, A. Cárdenas Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome J Hepatol 33 1 2000 43 48
76. R. Moreau, F. Durand, T. Poynard Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study Gastroenterology 122 4 2002 923 930
77. R. Ortega, P. Ginès, J. Uriz Terlipressin therapy with and without albumin for patients with hepatorenal syndrome Efficacy and outcome Hepatology 36 4, pt 1 2002 941 948
78. P. Solanki, A. Chawla, R. Garg, R. Gupta, M. Jain, S.K. Sarin Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial J Gastroenterol Hepatol 18 2 2003 152 156
79. S. Neri, D. Pulvirenti, M. Malaguarnera Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome Dig Dis Sci 53 3 2008 830 835
80. A. Sanyal, T. Boyer, G. Garcia-Tsao A prospective, randomized, double blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome (HRS) Gastroenterology 134 5 2008 1360 1368
81. M. Martin-Llahi, M.N. Pepin, G. Guevara Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study Gastroenterology 134 5 2008 1352 1359
82. L.L. Gluud, K. Christensen, E. Christensen, A. Krag Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome Hepatology 51 2 2010 576 584
83. A. Nazar, G.H. Pereira, M. Guevara Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome Hepatology 51 1 2010 219 226
84. T.D. Boyer, A.J. Sanyal, G. Garcia-Tsao Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics J Hepatol 55 2 2011 315 321
85. J.C. Velez, P.J. Nietert Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials Am J Kidney Dis 58 6 2011 928 938
86. P. Ginès Pharmacological management of hepatorenal syndrome Lessons from non-responders J Hepatol 55 2 2011 268 269
87. F. Wong, L. Pantea, K. Sniderman Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome Hepatology 40 1 2004 55 64
88. P. Angeli, R. Volpin, G. Gerunda Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide Hepatology 29 6 1999 1690 1697
89. C. Duvoux, D. Zanditenas, C. Hezode Effects of noradrenaline and albumin in patients with type 1 hepatorenal syndrome: a pilot study Hepatology 36 2 2002 374 380
90. L.P. Wong, M.P. Blackley, K.A. Andreoni, H. Chin, R.J. Falk, P.J. Klemmer Survival of liver transplant candidates with acute renal failure receiving renal replacement therapy Kidney Int 68 1 2005 362 367
91. S.R. Mitzner, J. Stange, S. Klammt Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial Liver Transpl 6 3 2000 277 286
92. R. Bañares, F. Nevens, F.S. Larsen Extracorporeal liver support with the molecular adsorbent recirculating system (MARS) in patients with acute-on-chronic liver failure (AOCLF) The RELIEF Trial [abstract 1184A] J Hepatol 52 suppl 1 2010 S459 S460
93. Kribben A, Gerken G, Haag S, et al. HELIOS Study Group. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure [published online ahead of print January 13, 2012]. Gastroenterology. doi:10.1053/j.gastro.2011.12.056.
94. F. Wong, N. Raina, R. Richardson Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment Gut 59 3 2010 381 386
95. M. Guevara, P. Ginès, J.C. Bandi Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems Hepatology 28 2 1998 416 422
96. K.A. Brensing, J. Textor, J. Perz Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study Gut 47 2 2000 288 295
97. J.D. Eason, T.A. Gonwa, C.L. Davis Proceedings of Consensus Conference on simultaneous liver kidney transplantation (SLK) Am J Transplant 8 11 2008 2243 2251
98. M.R. Charlton, W.J. Wall, A.O. Ojo Report of the first international liver transplantation society expert panel consensus conference on renal insufficiency in liver transplantation Liver Transpl 15 11 suppl 2 2009 S1 S34
99. J.P. Rice, C. Skagen, A. Said Liver transplantation outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin Transplantation 91 10 2011 1141 1147
100. T.D. Boyer, A. Sanyal, G. Garcia-Tsao Impact of liver transplantation for the survival of patients treated for hepatorenal syndrome type-1 Liver Transpl 17 11 2011 1328 1332
101. T. Restuccia, R. Ortega, M. Guevara Effects of treatment of hepatorenal syndrome before transplantation on post-transplantation outcome A case-control study J Hepatol 40 1 2004 2004 2006
102. P. Ginès Pharmacological therapy, hepatorenal syndrome, and liver transplantation Liver Transpl 17 11 2011 1244 1246
103. P. Ginès, J. Uriz, B. Calahorra Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis Gastroenterology 123 6 2002 1839 1847
104. E. Akriviadis, R. Botla, W. Briggs Pentoxifylline improves short term survival in severe acute alcoholic hepatitis: a double blind placebo controlled trial Gastroenterology 119 6 2000 1637 1648
105. P. Mathurin, A. Louvet, T. Dao Addition of pentoxifylline to prednisolone for severe alcoholic hepatitis does not improve 6 month survival: results of the Corpentox trial [abstract] Hepatology 54 4 2011 391A
106. A. Cárdenas, P. Ginès, P. Marotta Tolvaptan, an oral vasopressin antagonist in the treatment of hyponatremia in cirrhosis J Hepatol 56 3 2012 571 578
107. B.A. Runyon AASLD Practice Guidelines Committee Management of adult patients with ascites due to cirrhosis: an update Hepatology 49 6 2009 2087 2107